-
Naratriptan
- indication:For the acute treatment of migraine attacks with or without aura in adults.
- pharmacologypharmacology:
- mechanism: Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.
- toxicity: Symptoms of overdose include light-headedness, loss of coordination, tension in the neck, and tiredness.
- absorprion: Well absorbed (74% oral biovaility), absorption is rapid with peak plasma concentrations after 2-5 hours. The rate of absorption is slower during a migraine attack.
- halflife: 5-8 hours
- roouteelimination:
- volumedistribution: * 170 L
- clearance: * 6.6 mL/min/kg